Water-soluble and non-water-soluble extract, standardized to a declared mitragynine content — with laboratory-verified purity up to 97%. A member of the Biofarma Group.
SUBANG, WEST JAVA · SUPERVISED BY KEMENKES & BPOM · MEMBER OF BIOFARMA GROUP
Mitragyna speciosa (Korth.) Havil. is a tropical evergreen of the Rubiaceae family, native to Southeast Asia. Its leaf is rich in indole alkaloids, of which mitragynine is the most abundant.
Our extract concentrates that alkaloid from the dried leaf into a consistent, declared assay — so a downstream manufacturer receives a defined specification rather than variable raw botanical.
Each grade is standardized to a declared mitragynine content. The final assay for your order is confirmed at the contract stage.
Highest assay achieved to date: 95%
Highest purity achieved to date: 97%
Results below are the highest purity achieved on our 90%-up grade, confirmed by two independent methods, alongside acute-toxicity and heavy-metal testing.
Figures represent highest purity achieved to date, not a guaranteed release specification. Release specification is confirmed per contract.
Representative results for the 90%-up grade. Identity is confirmed by FTIR and NMR against a mitragynine reference.
| Parameter | Method / limit | Result |
|---|---|---|
| Mitragynine (identity) | FTIR / NMR — matches reference | Confirmed |
| Loss on drying | USP · ≤ 5% | 2.9% |
| Residue on ignition | USP · ≤ 0.1% | 0.04% |
| Residual solvent — toluene | ICH Q3C / USP · ≤ 890 ppm | 0.10 ppm |
| Residual solvent — benzene | ICH Q3C / USP · ≤ 2 ppm | 0.004 ppm |
| Heavy metals | Contaminant panel | Pass |
| Acute toxicity | LD50, oral | >5000 mg/kg |
Values are representative test results, not guaranteed release figures. A certificate of analysis accompanies each shipment; the release specification is agreed at contract. A documented pharmacological profile is available to qualified B2B partners under separate cover.
PT Sinkona Indonesia Lestari operates a pharmaceutical manufacturing facility under the supervision of the Indonesian Ministry of Health (Kemenkes) and the National Agency of Drug and Food Control (BPOM). That supervision applies to our alkaloid production operation.
Kratom extract is manufactured within the same facility, using the same quality system, laboratory, and lot-release discipline. Regulatory registration specific to the kratom extract is confirmed per destination market at the contract stage.
Part of Indonesia's state-owned pharmaceutical holding, alongside a heritage in cinchona alkaloid manufacturing.
Every lot is documented from intake to release, with a certificate of analysis and retained sample.
Established documentation and logistics from an operation that already exports pharmaceutical-grade alkaloids.